Go back

UK drugs agency unveils ‘quicker’ post-Brexit approval process


New pathway will ‘reduce the time to market for innovative medicines’, government says

The UK government has launched a “fast-track” approvals process for new treatments so they can be brought to the market faster—in a similar way that approvals for Covid-19 vaccines were sped up.

The move follows the UK’s exit from the European Union, which saw the responsibility of licensing drugs and medical products transferred from the European Medicines Agency to the UK Medicines and Healthcare products Regulatory Agency (MHRA).

This article is only available to *Research Professional subscribers. If you are a subscriber you can read the article in full on researchprofessional.com

Alternatively, Pivot-RP users can log in and view the article via this link.